Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Moehler, Markus ^a   Gockel, Ines ^a   Roessler, Hans Peter ^a   Arnold, Dirk ^b   Trarbach, Tanja ^c   Thomaidis, Thomas ^a   Klautke, Gunther ^d   Rödel, Claus ^e   Brenner, Baruch ^f   Lang, Hauke ^a   Galle, Peter R ^a   Schimanski, Carl C ^a   Schmidberger, Heinz ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemoradiotherapy; Docetaxel; Neoadjuvant radiochemotherapy; Oesophagogastric cancer oxaliplatin

Indexed keywords

DOCETAXEL; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DEHYDRATION; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS SURGERY; FATIGUE; FEMALE; FEVER; HEARTBURN; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PATIENT SAFETY; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; POSTOPERATIVE INFECTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; GERMANY; HUMANS; ISRAEL; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874150344     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-75     Document Type: Article

References (27)

1. Tan IT, So BY. Value of intensive follow-up of patients after curative surgery for gastric carcinoma. J Surg Oncol 2007, 96(6):503-506. 10.1002/jso.20823, 17680634.
2. Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 2009, 21(4):381-385. 10.1097/CCO.0b013e32832c42e0, 19412098.
3. Moehler M, Schimanski CC, Gockel I, Junginger T, Galle PR. (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change?. Dig Dis 2004, 22(4):345-350. 10.1159/000083597, 15812158.
4. Schurr PG, Yekebas EF, Kaifi JT, Lasch S, Strate T, Kutup A, Cataldegirmen G, Bubenheim M, Pantel K, Izbicki JR. Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. J Surg Oncol 2006, 94(4):307-315. 10.1002/jso.20582, 16917878.
5. Moehler M, Galle PR, Gockel I, Junginger T, Schmidberger H. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer. Pract Res Clin Gastroenterol 2007, 21(6):965-981.
6. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27(6):851-856. 10.1200/JCO.2008.17.0506, 19139439.
7. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335(7):462-467. 10.1056/NEJM199608153350702, 8672151.
8. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19(2):305-313.
9. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6(9):659-668. 10.1016/S1470-2045(05)70288-6, 16129366.
10. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26(7):1086-1092. 10.1200/JCO.2007.12.9593, 18309943.
11. Gaast AV, van Hagen P, Hulshof M, Richel D, van Berge Henegouwen MI, Nieuwenhuijzen GA, Plukker JJ, Bonenkamp JJ, Steyerberg EW, Tilanus HW, CROSS Study Group Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a mulitcenter randomized phase III study. J Clin Oncol 2010, 28:15s. CROSS Study Group.
12. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358(1):36-46. 10.1056/NEJMoa073149, 18172173.
13. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24(31):4991-4997. 10.1200/JCO.2006.06.8429, 17075117.
14. Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg 2006, 95(4):260-269.
15. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003, 98(7):1521-1530. 10.1002/cncr.11660, 14508841.
16. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29(13):1715-1721. 10.1200/JCO.2010.33.0597, 21444866.
17. Meluch AA, Greco FA, Gray JR, Thomas M, Sutton VM, Davis JL, Kalman LA, Shaffer DW, Yost K, Rinaldi DA, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003, 9(4):251-260. 10.1097/00130404-200307000-00007, 12967135.
18. Van Cutsem E, Boni C, Tabernero J, Massuti B, Richards DA, Prenen H, Steinberg I, Rougier P. Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. Proc ASCO 2011, 29(suppl). abstr 4018.
19. Gaast A, van Hagen P, Hulshof M, Richel D, van Berge HM, Nieuwenhuijzen G, Plukker J, Bonenkamp JJ, Steyerberg E, Tilanus H. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. Proc ASCO 2010, 28(15s):4004.
20. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997, 337(3):161-167. 10.1056/NEJM199707173370304, 9219702.
21. Dahn D, Martell J, Vorwerk H, Hess CF, Becker H, Jung K, Hilgers R, Wolff HA, Hermann RM, Christiansen H. Influence of Irradiated Lung Volumes on Perioperative Morbidity and Mortality in Patients After Neoadjuvant Radiochemotherapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 2009, 77(1):44-52.
22. Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA, Hainsworth JD. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 2010, 28(13):2213-2219. 10.1200/JCO.2009.24.8773, 20351330.
23. Solomon N, Mezentsev D, Reis I, Lima M, Rios J, Avisar E, Franceschi D, Livingstone A, Podolsky L, Ardalan B. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma. Jpn J Clin Oncol 2011, 41(4):469-476. 10.1093/jjco/hyq239, 21258083.
24. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003, 185(6):538-543. 10.1016/S0002-9610(03)00066-7, 12781882.
25. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007, 25(24):3719-3725. 10.1200/JCO.2006.10.4760, 17704421.
26. Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, Köberle D, Terraciano L, Schnider A, Bodis S, Popescu R, Swiss Group for Clinical Cancer Research (SAKK) Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol 2009, 20(9):1522-1528. 10.1093/annonc/mdp045, 19465425, Swiss Group for Clinical Cancer Research (SAKK).
27. Ruhstaller T, Templeton A, Ribi K, Schuller JC, Borner M, Thierstein S, von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Koeberle D, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie 2010, 33(5):222-228. 10.1159/000305094, 20502056.